The company's platform integrates genomic sequencing, clinical data analytics, and AI-driven insights across oncology, cardiology, and neuropsychiatry. Tempus serves more than 50% of U.S. oncologists ...

The AI medical imaging market is projected to hit nearly $20 billion by 2033, growing at a 34.7% CAGR([1]) . Echocardiography alone is forecast to grow to $2.64 billion by 2030 as hospitals demand ...

RadNet (NASDAQ:RDNT) executives highlighted record fourth-quarter results and outlined plans to accelerate growth in 2026, ...

RadNet (RDNT) reports record Q4 2025 revenue of $547.7M, up 14.8%, with Digital Health surging 48% and strong 2026 guidance driven by AI growth.

Based in Paris, France, Gleamer serves over 700 customer contracts worldwide with a broad portfolio of FDA-cleared and CE-marked solutions for musculoskeletal, breast, lung and neurologic applications ...

Lord Brady discovered he had the disease after taking a PSA blood test that indicates cancer risk. This was followed by two ...

King Faisal Specialist Hospital and Research Centre (KFSH) in Riyadh has successfully introduced a pioneering high-intensity focused ultrasound (HIFU) treatment for prostate cancer for the first time ...

Scientists comment on the Prostate Cancer Research report that reviews the economic model used to inform decisions on prostate cancer screening in the UK. Prof Hashim Ahmed, Professor of Urology, ...

Certain cancers can now be frozen inside your body. Yes, you heard it right. In what could be a significant leap in minimally invasive oncology, Liverpool Hospi ...

The methods of diagnosing and treating localised prostate cancer has changed significantly in the last two decades.

A dad ignored his frequent nightly bathroom trips — until a routine PSA test led to a shocking prostate cancer diagnosis and life-saving treatment.

Going to the bathroom at night (nocturia) might be a sign of prostate cancer, but usually, it's due to non-cancerous problems like an enlarged prostate (BPH) or other health concerns. Even though it ...